Speaker

Mazen Noureddin, MD, MHSc

Houston Methodist Hospital
Mazen Noureddin, MD, MHSc

Biography

Mazen Noureddin, MD, MHSc, did his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). There, he finished the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. He then joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013. He was then recruited to Cedars-Sinai Medical Center in 2015 and was appointed as the founding director of Fatty Liver Program.
Dr. Noureddin is internationally known for his research in MASLD/MASH and MASH related cirrhosis. He conducted more than 50 investigational clinical studies of novel treatments for NASH. He is an expert in non-invasive testing and biomarkers of NASH and cirrhosis. He has published in all these areas and has been invited to consensus panels on these topics by multiple international societies including the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of Liver Diseases (EASL), Asian Pacific Association for the Study of the Liver (APASL) and Latin American Association for the Study of the Liver (ALEH). He has given invited lectures on MASLD/MASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the chair of the AASLD MASLD special interest group, chair of the Annual Meeting Educational Committee and has been a member of many Special Program Committees. He has served on the editorial board for major GI journals including "Gastroenterology", "Hepatology" and "Clinical Gastroenterology and Hepatology (CGH)". He is an Associate Editor for "Clinical Gastroenterology and Hepatology (CGH)". Dr. Noureddin has been funded by the National Cancer Institute and has served as a reviewer on NIH study sections. He has published >225 papers in many journals including: The New England Journal of Medicine, the Lancet, Nature Medicine, Lancet Gastroenterology and Hepatology, Science Trinational Medicine, Journal of Hepatology, Journal of Clinical Investigation, Gastroenterology, Hepatology, Clinical Gastroenterology and Hepatology and others.

In May 2022, Dr. Noureddin moved to Houston, He is a Professor of Medicine Lynda K. and David M. Underwood Center for Digestive Disorders J.C. Walter Jr. Transplant Center Sherrie & Alan Conover Center for Liver Disease & Transplantation at Houston Methodist Hospital (currently ranked #8 in GI and GI surgery by US News) and Weill Cornell Medicine. He has also established the Houston Research Institute which is State of the Art facility that offers patients with liver disease access to new innovative non-invasive diagnostic tests and breakthrough therapies.

Sessions

8:00 AM - 5:30 PM
Nov 07 2025
Washington, D.C.

Postgraduate Course, Parts 1–4: A Lifetime of Liver Health (Ticketed)

Mary Rinella, MD, FAASLD, Presenter
Michael Trauner, Presenter
Raymond T Chung, MD, FAASLD, Presenter
Shira Zelber-Sagi, PhD, Presenter
Arun J Sanyal, MD, FAASLD, Presenter
Ramon Bataller, Presenter
Carla W Brady, MD, MHS, FAASLD, Presenter
Marialena Mouzaki, MD, Presenter
Silvia Vilarinho, MD, PhD, Presenter
Gideon M Hirschfield, MB BChir, PhD, FRCP (Lon), Presenter
Lily Dara, MD, Presenter
Jasmohan S. Bajaj, MD, FAASLD, Presenter
Jennifer C Lai, MD, MBA, Presenter
Fasiha Kanwal, MD, MSHS, AGAF, FAASLD, Presenter
Neehar D. Parikh, MD, MS, FAASLD, Presenter
Sumeet K. Asrani, MD MSc, Presenter
ALD
Hepatitis
Liver Cancer
MASLD
Transplant
4:00 PM - 5:30 PM
Nov 07 2025
Washington, D.C.

Obesity and Addiction Medicine in Liver Disease: Translating Science Into Practice, Part 2—Interventions and Long-Term Management (Ticketed)

Reem Z Sharaiha, MD MSc, Presenter
Brittany Bromfield, MD, Presenter
ALD
MASLD
8:00 AM - 9:30 AM
Nov 08 2025
Washington, D.C.

Steatotic Liver Disease: What You Need to Know, Part 1. Steatotic Liver Disease at the Crossroads—Bridging Alcohol-Associated Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the Era of Multimorbidity

Veeral Ajmera, MD, Presenter
Miriam B. Vos, MD, MSPH, FAASLD, Presenter
Brian P Lee, MD, Presenter
Gerald Scott Winder, MD MSc FACLP, Presenter
ALD
MASLD
2:00 PM - 3:30 PM
Nov 08 2025
Washington, D.C.

Steatotic Liver Disease: What You Need to Know, Part 2. Dual Threats—Advancing Research and Care in Steatotic Liver Disease

Shira Zelber-Sagi, PhD, Presenter
Jonathan G Stine, MD, MSc, Presenter
Naim Alkhouri, MD, FAASLD, Presenter
Alina M. Allen, MD, Presenter
Gene Im, MD, FAASLD, Presenter
ALD
MASLD
2:00 PM - 3:30 PM
Nov 09 2025
Washington, D.C.

General Update: Latest Advances in Hepatology

Vincent Chen, MD, Presenter
Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD, Presenter
ALD
MASLD
12:45 PM - 1:30 PM
Nov 10 2025
Washington, D.C.

MTE #40 Metabolic Dysfunction-Associated Steatohepatitis Therapeutic Agents: What Is Available and What Is Next in Line?

MASLD
3:45 PM - 4:45 PM
Nov 10 2025
Washington, D.C.

Clinical Research Workshop: Advancing Research Frameworks in MetALD Breakout Session, Part 2C—Designing Clinical Trials in MetALD

Mazen Noureddin, MD, MHSc, Presenter
ALD
MASLD